Last reviewed · How we verify
zamtocabtagene autoleucel
At a glance
| Generic name | zamtocabtagene autoleucel |
|---|---|
| Sponsor | Miltenyi Biomedicine GmbH |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (PHASE2)
- Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms (PHASE2)
- DALY II USA/ MB-CART2019.1 for DLBCL (PHASE2)
- US Zamto-cel Autoimmune Diseases (PHASE1)
- Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- zamtocabtagene autoleucel CI brief — competitive landscape report
- zamtocabtagene autoleucel updates RSS · CI watch RSS
- Miltenyi Biomedicine GmbH portfolio CI